FDA Grants Fast Track Designation to SOT109 in CRC
“Advanced colorectal cancer remains an area of profound unmet need, particularly for patients whose disease has progressed after standard therapies,” said Vivi Boura, M.D., chief medical officer of SOTIO. “SOT109 is designed to capitalize on the unique biology of CDH17, a highly prevalent target that is broadly and consistently expressed across colorectal tumors, while having limited expression in healthy tissues. We believe Fast Track Designation underscores both the urgent need for new treatment options and the potential of SOT109 to expand the benefits of targeted ADC therapy to a substantially broader patient population.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data